Skip to main content

Market Overview

UPDATE: Stifel Reiterates On Ophthotech Corp Following 3Q14 Report

Share:

In a report published Wednesday, Stifel analyst Stephen Willey reiterated a Buy rating on Ophthotech Corp (NASDAQ: OPHT), and raised the price target from $58.00 to $59.00.

In the report, Stifel noted, “P3 enrollment remains on track and the tivozantib licensing agreement creates some additional low-cost optionality. Increased $59 target (previously $58) reflects refinement of Novartis milestone payments. Remain Buy-rated.”

Ophthotech Corp closed on Tuesday at 41.74.

Latest Ratings for OPHT

DateFirmActionFromTo
Mar 2018JP MorganDowngradesNeutralUnderweight
Feb 2018Chardan CapitalMaintainsNeutralNeutral
Dec 2016Gabelli & Co.DowngradesBuyHold

View More Analyst Ratings for OPHT

View the Latest Analyst Ratings

 

Related Articles (OPHT)

View Comments and Join the Discussion!

Posted-In: Stephen Willey StifelAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com